Bengaluru: An Indian study has challenged a long-held assumption in blood-based cancer detection, finding that DNA released by white blood cells (WBCs) may strengthen, rather than dilute, tumour-related signals in the bloodstream. The findings could offer new insights into why the sensitivity of blood-based cancer tests varies among patients, including those diagnosed at the same stage of disease.
The four-year study examined CancerSpot, a multi-cancer early detection test developed by Strand Life Sciences, a genomics subsidiary of Reliance Industries. The test combines DNA sequencing with Artificial Intelligence (AI) to identify methylation patterns, or chemical modifications of DNA, that help distinguish cancer-associated fragments from those originating in normal cells.
Recently published in the Proceedings of the National Academy of Sciences (PNAS), the research found that higher levels of circulating cell-free DNA in cancer patients were associated with stronger cancer-related signals and improved detection sensitivity, even among patients at the same stage of cancer.
Conducted across 43 hospitals in India, the study analysed blood samples from 1,480 participants, including patients with 14 types of cancer and healthy individuals. It examined the biological factors influencing the detection of cancer-associated signals in the bloodstream.
The central finding challenges the assumption that an increase in DNA released by white blood cells would make it harder to identify the much smaller fraction originating from tumours. Researchers found that tumour and immune-cell contributions to circulating DNA appeared to increase in synchrony, with tumour-derived signals keeping pace with, and in some cases outpacing, the increase in immune-cell DNA.
The difference was particularly evident in early-stage disease. Among Stage I cancer patients, the detection rate was 52 per cent in those with lower levels of circulating DNA, compared with 85 per cent among those with higher levels. The finding suggests that total cell-free DNA concentration could be an important variable in understanding the sensitivity of blood-based cancer detection tests, alongside conventional tumour staging.
In an independent validation cohort, CancerSpot reported an overall sensitivity of 72 per cent and a false-positive rate of 1.4 per cent. The test also identified the likely tissue or location of cancer in approximately 76 per cent of cases.
The findings could have implications for how emerging multi-cancer early detection technologies are evaluated. Cancer detection studies have traditionally assessed sensitivity according to tumour stage, with early-stage cancers generally more difficult to identify. The research suggests that total circulating DNA levels could provide an additional measure for understanding why detection rates vary between patients at the same stage.
Commenting on the publication, Dr Ramesh Hariharan, CEO, Strand Life Sciences, said, “In early cancer detection, clinical utility depends on walking a tightrope: maximizing sensitivity to catch disease early while minimizing false-positives that lead to unnecessary invasive procedures and patient harm. Achieving that balance requires deep scientific insight and rigorous validation. Having our work published in PNAS attests to the rigor of our science and the quality of our clinical evidence, marking a pivotal milestone in our mission to bring reliable, scalable early detection beyond the current standard-of-care, to India.”
The research comes amid growing interest in blood-based multi-cancer screening technologies, which aim to detect cancer signals through a single blood draw rather than relying exclusively on organ-specific screening methods.
Unlike conventional imaging techniques, which primarily identify tumours based on their size, DNA methylation-based tests look for molecular signals released by tumour cells into the bloodstream. These approaches could potentially complement existing screening pathways, particularly for cancers that currently lack established population-level screening recommendations.
However, such tests are not diagnostic tools and cannot replace established screening methods such as mammography, colonoscopy or low-dose CT scans. A positive result indicates the need for further clinical evaluation through targeted imaging, endoscopy and, where indicated, biopsy. A negative result also does not rule out cancer.

